Kidswell Bio Corporation (4584)

Market cap
¥12B
P/E ratio
KidsWell Bio develops biosimilar drugs and regenerative medicine treatments using SQ-SHED stem cells from baby teeth for pharmaceutical partners and rare disease patients.
Period EndReturn on Assets (Million JPY)YoY (%)
Mar 31, 2025-0.3-98.89%
Mar 31, 2024-31.7+78.22%
Mar 31, 2023-17.8+23.49%
Mar 31, 2022-14.4-45.92%
Mar 31, 2021-26.6-87.74%
Mar 31, 2020-217+682.51%
Mar 31, 2019-27.7+3.16%
Mar 31, 2018-26.9-40.73%
Mar 31, 2017-45.3-18.21%
Mar 31, 2016-55.4
AI Chat